Servicio de Urgencias, Unidad de Corta Estancia y Hospitalización a Domicilio, Hospital General de Alicante; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIALFundación FISABIO), Alicante, España. Grupo Multidisciplinar Español para el Soporte Terapéutico con Terapia de Alto Flujo en Adultos (HISPAFLOW).
Servicio de Neumología, Hospital Universitario Ramón y Cajal, Madrid, España. Grupo Multidisciplinar Español para el Soporte Terapeútico con Terapia de Alto Flujo en Adultos (HISPAFLOW).
Emergencias. 2018;30(6):395-399.
To evaluate the efficacy and safety of high-flow nasal cannula (HFNC) oxygen therapy in patients in acute respiratory failure due to acute heart failure (AHF) refractory to conventional oxygen therapy or noninvasive ventilation.
Prospective observational study of patients with AHF and respiratory failure attended in an emergency department whose condition worsened after they were admitted to a short-stay unit, leading to use of HFNCs. Efficacy was assessed using a modified Borg dyspnea scale and oxygenation variables on discharge from the emergency department. Data were recorded after 24 hours on conventional oxygen therapy and after 60 and 120 minutes and 24 hours of HFNC therapy. Safety outcomes were the degree of patient comfort and the frequency of adverse events.
Prospective observational study of patients with AHF and respiratory failure attended in an emergency department whose condition worsened after they were admitted to a short-stay unit, leading to use of HFNCs. Efficacy was assessed using a modified Borg dyspnea scale and oxygenation variables on discharge from the emergency department. Data were recorded after 24 hours on conventional oxygen therapy and after 60 and 120 minutes and 24 hours of HFNC therapy. Safety outcomes were the degree of patient comfort and the frequency of adverse events.
HFNC oxygen therapy offers a treatment alternative for patients with acute respiratory failure due to AHF.
评估高流量鼻导管（HFNC）氧疗对急性心力衰竭（AHF）所致急性呼吸衰竭患者的疗效和安全性，这些患者对常规氧疗或无创通气无反应。
前瞻性观察性研究，纳入在急诊科就诊的 AHF 合并呼吸衰竭患者，这些患者在入住短期留观病房后病情恶化，需要使用 HFNC。疗效评估采用改良的 Borg 呼吸困难量表和急诊科出院时的氧合变量。分别在常规氧疗 24 小时后、HFNC 治疗 60、120 分钟和 24 小时后记录数据。安全性结局为患者舒适度程度和不良事件发生频率。
HFNC 氧疗为 AHF 所致急性呼吸衰竭患者提供了一种治疗选择。
